Chargement en cours...
Simultaneous Inhibition of BCR-ABL1 Tyrosine Kinase and PAK1/2 Serine/Threonine Kinase Exerts Synergistic Effect against Chronic Myeloid Leukemia Cells
Tyrosine kinase inhibitors (TKIs) revolutionized the treatment of chronic myeloid leukemia in the chronic phase (CML-CP). However, it is unlikely that they can completely “cure” the disease. This might be because some subpopulations of CML-CP cells such as stem and progenitor cells are resistant to...
Enregistré dans:
| Publié dans: | Cancers (Basel) |
|---|---|
| Auteurs principaux: | , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
MDPI
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6826736/ https://ncbi.nlm.nih.gov/pubmed/31614827 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers11101544 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|